Suppr超能文献

美国自闭症谱系障碍患者的精神共病和精神药物使用情况。

Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States.

机构信息

Real World Data-Science, Product Development, F. Hoffmann-La Roche, Ltd, Hochstrasse 4, Basel, 4053, Switzerland.

Neuroscience, Ophthalmology, and Rare Diseases (NORD), Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, 4070, Switzerland.

出版信息

Autism Res. 2017 Dec;10(12):2037-2047. doi: 10.1002/aur.1848. Epub 2017 Sep 30.

Abstract

This study investigated psychotropic medication usage in two large, cohorts of people with autism spectrum disorder (ASD) throughout the calendar year 2014. The cohorts referred to individuals with commercial (employer-sponsored) and Medicaid insurance in the United States. We aimed to understand prescribing patterns of such medications across a wide age-range and in the presence/absence of other clinical and non-clinical characteristics, including psychiatric comorbidities. We described the prevalence and length of prescriptions by age, psychiatric comorbidity and overall. We also fitted multivariable logistic regression models to describe the relationship between treatments and subject characteristics simultaneously. Eighty percent of the identified population was male, although gender did not impact the odds of receiving medication. Medication use was strongly associated with age, increasing most rapidly before adulthood; generally plateauing thereafter. All psychiatric comorbidities studied also individually increased the chances of medication use, with epilepsy and ADHD having the highest associations in both the commercial (OR > 7) and Medicaid (OR around 12) cohorts. Those in non-capitated insurance plans, in foster care and white individuals also had increased odds of prescriptions. Overall, slightly more Medicaid enrollees received any psychotropic treatment (commercial: 64%, Medicaid: 69%). Nonetheless in both cohorts, a large proportion of individuals received treatment even without a diagnosis of any other psychiatric comorbidity (commercial: 31%, Medicaid: 33%). In summary, this report sheds new light on the latest patterns of psychiatric comorbidity profile and psycho-pharmacological treatment patterns in ASD Autism Res 2017, 10: 2037-2047. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: this study identified a large number of children and adults in the US with autism spectrum disorder (autism) from employer-sponsored and government funded (Medicaid) health insurance data. Psychotropic medications were used by over two thirds of people, and four in ten people received two medications at the same time. The chances of receiving medication increased for individuals with other psychiatric conditions (e.g., ADHD), and also increased with age.

摘要

这项研究调查了 2014 年全年两个大型自闭症谱系障碍(ASD)队列人群中精神药物的使用情况。这两个队列是指美国有商业(雇主赞助)和医疗补助保险的个人。我们旨在了解在广泛的年龄范围内,以及在存在/不存在其他临床和非临床特征(包括精神共病)的情况下,此类药物的处方模式。我们按年龄、精神共病和总体情况描述了处方的流行率和长度。我们还拟合了多变量逻辑回归模型,同时描述了治疗与受试者特征之间的关系。确定的人群中 80%为男性,尽管性别并未影响接受药物治疗的几率。药物使用与年龄密切相关,在成年前增长最快;此后一般趋于平稳。研究中的所有精神共病也单独增加了药物使用的机会,在商业(OR>7)和医疗补助(OR 约为 12)队列中,癫痫和 ADHD 的关联最高。非统包保险计划、寄养和白人个体也有更高的处方几率。总体而言,略多于医疗补助受保人接受任何精神药物治疗(商业:64%,医疗补助:69%)。尽管如此,在两个队列中,即使没有其他任何精神共病的诊断,仍有很大一部分人接受了治疗(商业:31%,医疗补助:33%)。总之,本报告揭示了 ASD 最新的精神共病特征和精神药理学治疗模式,为自闭症研究提供了新的视角。Autism Res 2017, 10: 2037-2047。© 2017 国际自闭症研究协会,威利在线期刊,公司。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验